"In the middle of the summer Abera Bioscience, that has been listed on Spotlight Stock Market since 2021, pulled off a capitalization on their own, via a share issue of SEK 21.5 million, largely supported by existing investors. The money will finance GMP manufacturing and a Phase I study of Aberas nasal, pneumococcal vaccine. Through Abera we contacted the U.S.-based lead investor Gunnar Sachs for a short interview."
Du måste logga in eller registrera dig för att svara på tråden.
